Inbox Robot - Choose newsletter content

Choose content

Enter keywords to create a newsletter

Create account

Enter your registration information

Set preferences

Set up your newsletter name, delivery and time zone preferences

Hint: Enter different keywords to generate new results.

Now you can:

Search the news index.
Browse more than 1 million newsletters by category.
Use preset newsletters:
- Aromatase Inhibitors
- Aromatase Inhibitors & Breast Cancer

Aromatase Inhibitors Newsletter

US FDA approves Eli Lilly's Inluriyo for adults with ER+, HER2─, ESR1─mutated advanced or metastatic breast cancer 27 Sep 2025 09:32 GMT
… MBC following recurrence on adjuvant aromatase inhibitor (AI), +/- prior CDK4 … progressed during or following an aromatase inhibitor (AI) therapy with or without …
<![CDATA[FDA Approves Inluriyo for ESR1-Mutated Advanced Breast Cancer Based on Phase III EMBER-3 Trial Data]]> 27 Sep 2025 00:47 GMT
… disease recurred or progressed after aromatase inhibitor therapy with or without a …
What you need to know about breast cancer 26 Sep 2025 22:26 GMT
… selective estrogen receptor modulators and aromatase inhibitors, may be used. Because these …
Lilly brings second oral SERD to market for breast cancer 26 Sep 2025 15:44 GMT
… after first-line treatment with aromatase inhibitor-based endocrine therapy, and the … compared to endocrine therapy with aromatase inhibitor exemestane or injectable SERD fulvestrant …
Lilly’s Oral SERD Wins FDA Go-Ahead for Breast Cancer 26 Sep 2025 12:58 GMT
… progressed after treatment with an aromatase inhibitor. Participants were randomized to receive …
Eli Lilly Inluriyo gets USFDA nod for adults with advanced breast cancer 26 Sep 2025 10:14 GMT
… MBC following recurrence on adjuvant aromatase inhibitor (AI), +/- prior CDK4 …
Imlunestrant Approved for ESR1-Mutated Advanced BC 26 Sep 2025 09:13 GMT
… breast cancer generally includes an aromatase inhibitor and a cyclin-dependent kinase … -1 mutation that makes the aromatase inhibitor less effective. In those cases … with either fulvestrant or the aromatase inhibitor exemestane, or a combination arm …
Eli Lilly's oral SERD Inluriyo passes muster with FDA in breast cancer 26 Sep 2025 01:43 GMT
… cancer following progression on an aromatase inhibitor. While the study also recruited …
<![CDATA[CDK4/6 Inhibitors in Visceral Crisis and in Patients With Positive Lymph Nodes]]> 26 Sep 2025 00:20 GMT
… CDK4/6 inhibitors with aromatase inhibitors in extensive visceral involvement, while …
<![CDATA[FDA-Approved CDK4/6 Inhibitors for Early and Metastatic Breast Cancer]]> 26 Sep 2025 00:20 GMT
… survival advantages when combined with aromatase inhibitors, compared to 16 months with …

Satisfied with the content?

Continue to create your account.

Choose content

Create account

Set preferences

EIN MARKETING SOLUTIONS

EIN NEWS SERVICES

ALL NEWS PUBLICATIONS